The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.
Age 18-85 ;
Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;
Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed.
Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;
The presence of a contraindication to thrombolytic therapy of ischemic stroke;
Pregnancy or lactation.
Men and women aged 18 to 85 years (inclusive), who meet the inclusion criteria and do not have contraindications for thrombolysis, with a diagnosis of acute ischemic stroke.
Case-only
Other
Not listed
Proportion of intracerebral hemorrhage
Number and proportion of intracerebral bleeding of any type, which occurs as a complication of thrombolytic treatment
Click on the lead sponsor to view all of their trials.
